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O B J E C T I V E S The aim of this study was to use multidetector computed tomography (MDCT) to
assess therapeutic effects of myocardial regenerative cell therapies.
B A C KG ROUND Cell transplantation is being widely investigated as a potential therapy in heart failure.
Noninvasive imaging techniques are frequently used to investigate therapeutic effects of cell therapies in the
preclinical and clinical settings. Previous studies have shown that cardiac MDCT can accurately quantify
myocardial scar tissue and determine left ventricular (LV) volumes and ejection fraction (LVEF).
METHOD S Twenty-two minipigs were randomized to intramyocardial injection of phosphate-
buffered saline (placebo, n  9) or 200 million mesenchymal stem cells (MSC, n  13) 12 weeks after
myocardial infarction (MI). Cardiac magnetic resonance and MDCT acquisitions were performed before
randomization (12 weeks after MI induction) and at the study endpoint 24 weeks after MI induction.
None of the animals received medication to control the intrinsic heart rate during ﬁrst-pass acquisitions
for assessment of LV volumes and LVEF. Delayed-enhancement MDCT imaging was performed 10 min
after contrast delivery. Two blinded observers analyzed MDCT acquisitions.
R E S U L T S MDCT demonstrated that MSC therapy resulted in a reduction of infarct size from 14.3 1.2% to
10.3  1.5% of LV mass (p  0.005), whereas infarct size increased in nontreated animals (from 13.8  1.3% to
16.5 1.5%; p 0.02) (placebo vs. MSC; p 0.003). Both observers had excellent agreement for infarct size (r
0.96; p 0.001). LVEF increased from32.6 2.2% to 36.9 2.7% inMSC-treated animals (p 0.03) anddecreased
in placebo animals (from 33.3  1.4% to 29.1  1.5%; p  0.01; at week 24: placebo vs. MSC; p  0.02). Infarct
size, end-diastolic LV volume, and LVEF assessed by MDCT compared favorably with those assessed by cardiac
magnetic resonance acquisitions (r  0.70, r  0.82, and r  0.902, respectively; p  0.001).
CONC L U S I O N S This study demonstrated that cardiac MDCT can be used to evaluate infarct size,
LV volumes, and LVEF after intramyocardial-delivered MSC therapy. These ﬁndings support the use of
cardiac MDCT in preclinical and clinical studies for novel myocardial therapies. (J Am Coll Cardiol Img
2011;4:1284–93) © 2011 by the American College of Cardiology Foundation
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1285ardiac imaging techniques play a critical
role in the evaluation of novel therapies
providing reliable surrogate endpoints in
the ongoing effort to explore new ap-
roaches to treat heart diseases. Myocardial trans-
lantation of different cell types and preparations
as been widely investigated as a potential therapy
or myocardial infarction (MI) and heart failure
HF) in recent years (1). Cardiac magnetic reso-
ance (CMR) is one of the preferred imaging tools,
n addition to the frequently used echocardiography
nd nuclear techniques, to provide reliable assess-
ent of left ventricular ejection fraction (LVEF)
nd infarct size, which are generally accepted sur-
ogate endpoints (2,3). Previous animal studies
sing CMR showed that mesenchymal stem cells
MSC) reduced infarct size and improved left
entricular (LV) function in acute and chronic MI
4–6). However, the use of CMR in the clinical
etting is limited in patients with metallic implants
nd pacemakers and is relatively complex and time
onsuming.
Over the last decade, multidetector computed
omography (MDCT) has emerged as a novel
omographic cardiac imaging modality. Improve-
ent in spatial and temporal resolution has allowed
he implementation of myocardial applications,
hich are necessary to evaluate regenerative thera-
ies. Although these MDCT applications are still
nvestigative, current MDCT technology is able to
rovide reliable and reproducible assessment of
ardiac function (7,8), myocardial viability with
elayed contrast enhancement (DCE) (9–11), and
yocardial blood flow (MBF) (12–14). However,
hether MDCT can be used for follow-up studies
nd is able to show therapeutic effects of regenera-
ive cell therapies has not been investigated. Ac-
ordingly, the purpose of this study was to 1) use
DCT LV function and myocardial viability as
urrogate endpoints in a randomized animal study
o evaluate outcomes of intramyocardial-delivered
ell therapy and 2) evaluate the robustness and
omparability of MDCT in relation to CMR.
M E T H O D S
Animal model. All animal studies were approved by
he Johns Hopkins University Institutional Animal
are and Use Committee and complied with the
Guide for the Care and Use of Laboratory Animals”
National Institutes of Health publication 80-23, revised
985). Thirty-three female Göttingen minipigs were
urchased from Marshall BioResources (North Rose, mew York). MIs were induced by occlusion of the
id-left anterior descending artery with an inflated
oronary angioplasty balloon as previously described
15). Five animals did not survive the infarct pro-
edure. Two animals died during the early
ollow-up in the first 4 days after MI induction, and
animals died between weeks 8 and 12 post-MI.
herefore, a total of 22 animals were used in the
tudy.
Cell harvest and isolation. The 13 animals random-
zed to cell therapy received bone marrow–derived
orcine MSC. MSC were obtained, isolated, and
xpanded as previously described (6). In brief, MSC
ere harvested when they reached 80% to 90%
onfluence. Cells were placed in cryo bags at a
oncentration of 10 to 15 million MSC/ml and
hen frozen in a control-rate freezer to
180°C until the day of implantation.
rypan blue staining was performed to
ttest viability of thawed MSC lots before
njection. Only MSC lots containing 85%
r more of viable cells were used in the
tudy.
Cell transplantation procedures. Twelve
weeks after MI, animals were randomized
to receive either intramyocardial injections
of porcine MSC or phosphate-buffered
saline to serve as a treatment (n  13) or
placebo (n  9) group, respectively. Myo-
cardial injections were performed as pre-
viously described (5,6).
Cardiac MDCT. MDCT images were ac-
uired at 2 time points, before randomiza-
ion at week 12 post-MI and 12 weeks
fter the intramyocardial injection proce-
ure at week 24.
IMAGE ACQUISITION. Each animal was
canned with electrocardiographic (ECG) monitor-
ng using a 0.5 mm  64-slice MDCT scanner
Aquilion 64, Toshiba Medical Systems Corpora-
ion, Otawara, Japan). Data acquisition for LV
unction parameters and LV volumes were initiated
anually at a threshold value of 180 Hounsfield
nits in the descending aorta. A 60-ml bolus of
odixanol (Visipaque 320 mg iodine/ml, Amersham
ealth, Buckinghamshire, United Kingdom) was
njected intravenously at rate of 5.0 ml/s,
pacifiying the LV chamber during first pass. An
dditional 90 ml of iodixanol was given intrave-
ously after first-pass acquisitions, and DCE
mages were acquired 10 min after initial contrast
elivery; 150 ml of iodixanol (0.91  0.04  103
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1286human equivalent dose of contrast currently used
for MDCT angiography.
During MDCT acquisition, respiration was sus-
pended and imaging was performed using a retro-
spective ECG-gated MDCT protocol without dose
modulation. Imaging parameters: gantry rotation
time  400 ms; detector collimation  0.5 mm 
64 (isotropic voxels  0.5  0.5  0.5 mm3  13
inepairs/cm); helical pitch variable depending on
eart rate (range 6.4 to 6.8); tube voltage 120 kV;
nd tube current  400 mA. Animals with heart
ates 100 beats/min during first-pass acquisition
eceived intravenous metoprolol (2 to 5 mg) and /or
miodarone (50 to 150 mg) to achieve lower heart
ate for DCE acquisitions.
IMAGE RECONSTRUCTION AND ANALYSIS. All raw
ata were reconstructed at contiguous 0.5-mm slice
hickness by an adaptive multisegment reconstruc-
ion algorithm (16). First-pass acquisitions were
econstructed in 10% steps from 0% to 90%
hroughout the entire R-R interval using a standard
ernel (FC43); images were reformatted at 4-mm
lice thickness in short axis and evaluated in QMass
T 7.1 (Medis Medical Imaging Systems, Leiden,
he Netherlands). Endocardial and epicardial bor-
ers of the LV were defined in all 10 contiguous
lices, and each end-diastolic and end-systolic frame
as determined to calculate LVEF, left ventricular
nd-diastolic volume (LVEDV), left ventricular
nd-systolic volume (LVESV), LV stroke volume,
nd LV remodeling parameters. The temporal res-
lution based on gantry rotation of all MDCT
cquisitions was 211.5  5.4 ms.
DCE-MDCT data (for myocardial scar assess-
ent) were reconstructed at 80% of the R to R=
nterval using the FC43 kernel and multisegment
econstruction. ECG editing to account for ar-
hythmias was performed when necessary. Multi-
lanar reformation at 4-mm slice thickness in the
hort axis of the heart was implemented, and
DCT images were analyzed using a custom
esearch software package (Cine Tool, GE Medical
ystems, Waukesha, Wisconsin). Infarct mass/
olumes in DCE-MDCT images were defined by 3
D of the signal intensity above the viable myocar-
ium for the core infarct and 2 SD for the peri-
nfarct zone as described (16). Infarct size was
efined as infarct mass as a percentage of LV mass.
oth datasets, the cine MDCT acquisitions, and
CE-MDCT images, were analyzed by 2 blindedbservers.CMR imaging. CMR was performed at the same
ime points as MDCT imaging in random order on
1.5-T MR scanner (CV/i, GE Medical Systems).
IMAGE ACQUISITION. LVEF function and LV vol-
mes were assessed using a steady-state free preces-
ion pulse sequence (17). Six to 8 contiguous
hort-axis slices were prescribed to cover the entire
V, from base to apex. Image parameters were as
ollows: repetition time/echo time 4.2 ms/1.9 ms;
ip angle  45°; 256  160 matrix; 8-mm slice
hickness/no gap; 125 kHz; 28-cm field of view,
nd 1 number of signals averages. After an intrave-
ous injection of gadolinium–diethylene triamine
entaacetic acid (0.2 mmol/kg body weight, Magn-
vist, Berlex, Wayne, New Jersey), DCE-CMR
mages were acquired 15 min later using an ECG-
ated, breath-hold, interleaved, inversion recovery,
nd fast gradient echo pulse sequence. DCE-CMR
mages were acquired in the same location as the
hort-axis cine images. Imaging parameters were
epetition time/echo time/inversion time  7.3
s/3.3 ms/180 to 240 ms; flip angle  25°; 256 
96 matrix; 8-mm slice thickness/no gap; 31.2 kHz;
8-cm field of view, and 2 number of signal
verages. Inversion recovery time was adjusted as
eeded to null the normal myocardium (16).
IMAGE ANALYSIS. Cine MR images were analyzed
with QMass MR 7.1 (Medis Medical Imaging
Systems). To evaluate LVEF, LV volumes and
myocardial mass endocardial and epicardial borders
were defined each in the end-diastolic and end-
systolic frame in 25 to 30 contiguous slices, and LV
parameters and volumes were calculated. The tem-
poral resolution of the cine MR images was 21.6 
0.9 ms. DCE-CMR images were analyzed on the
same custom research software package (Cine Tool,
GE Medical Systems) as DCE-MDCT images.
Infarct size, determined by infarct mass as a per-
centage of LV mass and infarct volume in DCE-
CMR images, was defined with the same threshold
method described for DCE-MDCT analysis.
Statistical analysis. All data are presented as mean
SEM unless otherwise stated. For infarct size and
infarct volume comparison, Pearson correlation and
linear regression analysis were used to compare
MDCT and CMR. Results were confirmed by
Bland-Altman analysis and agreement expressed as
mean  SD difference between methods at 95%
confidence intervals. The MDCT and CMR data
were evaluated with a paired Student t test. All
analyses were performed in MedCalc (MedCalc
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1287Software, Mariakerke, Belgium). A value of p 
0.05 was considered significant.
R E S U L T S
Baseline conditions. Twenty-two animals were used
n this study 12 weeks after MI induction (91.9 2.6
ays and 87.9  2.0 days after MI induction for
lacebo and MSC groups, respectively; p  0.19).
fter randomization, animals in both groups were of
imilar age (16.8  0.7 months and 15.5  1.1
onths for placebo and MSC, respectively; p 0.35)
nd body weight (39.3 1.6 kg and 35.7 1.9 kg for
lacebo and MSC, respectively; p  0.11).
Infarct size and scar volume. One placebo- and 2
MSC-treated animals were excluded from analysis
due to poor imaging quality caused by motion
artifacts at week 24. Infarct size, defined as infarct
mass as percentage of LV mass, was reduced in all
MSC-treated animals at week 24, whereas infarct
size increased in all animals in the placebo group
(Fig. 1). We observed a mean expansion of 29.1 
5.7% in infarct scar volume in the placebo group
(p  0.001). MSC therapy had limited effect on
otal scar volume (p  0.1) (Figs. 1, 2C, and 2D).
At week 24, infarct size and infarct volume were
reduced in MSC-treated animals compared with
those in the placebo group (p  0.003 and p 
0.01, respectively), (Table 1, Figs. 2A to 2D).
Global LV function and LV volumes. Cardiac MDCT
emonstrated that the decrease in infarct size re-
ulted in 14.0  6.7% improvement in LVEF in
nimals randomized to MSC therapy, whereas
VEF decreased by 12.3  3.1% in the placebo
roup (Table 1, Figs. 2E and 2F). Of note, 2
nimals that received MSC therapy did not show
mproved LVEF (Fig. 2F). All MDCT data for
lobal LV function and LV volumes are summa-
ized in Table 1.
Interobserver variability. Interobserver correlation
or infarct size, total infarct volume, LVEF, and
VEDV were excellent (r  0.96, r  0.98, r 
.93, and r  0.93, respectively) in MDCT acqui-
itions. The complete data are presented in Table 2.
MDCT comparison with CMR. MDCT and CMR
were performed on the same day in random order
within 2 h following the first imaging study. Three
animals had to be excluded from the analysis because
CMR image data were not obtained on the day
of the MDCT imaging. In 32 CMR studies, available
the same day as MDCT acquisitions, we found fair
agreement for infarct size, infarct volume, LVEF, and
LVEDV (Fig. 3, Table 3). In addition, LVESVshowed a good correlation with both imaging modal-
ities (r  0.81; p  0.001). Bland-Altman analysis
revealed a slight overestimation by 1.4 ml (95%
confidence intervals: 16.3 to 13.6) with MDCT.
Table 4 shows a direct comparison of all MDCT and
MRI values at the 2 time points.
Finally, we showed that MDCT and CMR
demonstrate similar effectiveness of MSC therapy
from week 12 to week 24 (Fig. 4). Infarct size
decreased by mean values of 4.7 1.1 ml and 6.2
2.0 ml when evaluated with DCE-MDCT and
DCE-CMR in MSC-treated animals, respectively
(p  0.43). The changes in LVEF with MSC
treatment were also apparent with both imaging
modalities, with comparable mean values (4.5 1.0
ml and 5.6 1.3 ml, MDCT vs. MRI, respectively;
p  0.4). The changes between the placebo- and
MSC-treated animals were also detected with both
imaging modalities. Although the detected differences
between MDCT and MRI were not significant for all
infarct and functional parameters, the changes over time
correlated with the assessment (Fig. 4).
D I S C U S S I O N
This is the first study to use cardiac MDCT for the
Figure 1. Infarct Assessment With DCE-MDCT
Example of delayed contrast enhancement multidetector computed
tomography (DCE-MDCT) images for a placebo-treated (A and B) an
mesenchymal stem cell (MSC)–treated (C and D) animal at 24 week
DCE images were reconstructed in the short axis at 4-mm slice thic
ness. (B and D) show the slices of the placebo-treated (A) and MSC
treated (C) animals, respectively, with a computer-generated mask
depicting the infarct area in red.d a
s.
k-
-evaluation of therapeutic effects of cell therapy on
2 animals.
mesenchymal stem cell.
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1288infarct size, LV volumes, and LV function. Our
results suggest that MDCT imaging reliably as-
sessed LVEDV, LVEF, infarct size, and infarct
volumes with DCE acquisitions; MDCT imaging
Impact of MSC Therapy Assessed by MDCT
animals (n  8) showed an increase in infarct size (A) and
me (C) at week 24, whereas intramyocardial delivery of MSC
farct size (B) and stabilized infarct volume (D) in all treated ani-
11). (E and F) Left ventricular ejection fraction (LVEF) was
at week 24 in placebo animals, whereas it increased in most
d animals; however, the treatment failed to improve LVEF in
MI  myocardial infarction; other abbreviations as in Figure 1.
s, LV Function, and LV Volumes by MDCT
Group Week 12 Week 24 p Value
ass Placebo 13.8 1.3 16.3 1.6 0.005
MSC 14.3 1.2 9.9 1.3* 0.001
l Placebo 4.7 0.6 6.2 0.7 0.001
MSC 4.4 0.4 3.6 0.5† 0.1
Placebo 33.6 1.1 37.5 1.6 0.02
MSC 30.6 1.3 37.4 2.1‡ 0.0003
Placebo 33.3 1.4 29.1 1.5 0.01
MSC 32.6 2.2 36.9 2.7§ 0.03
Placebo 19.7 1.6 19.4 0.8 0.81
MSC 15.1 0.7 20.6 1.6‡ 0.004
Placebo 60.1 5.7 67.6 4.1 0.16
MSC 48.1 3.1 56.3 4.3‡ 0.01
Placebo 40.4 4.5 48.3 3.7 0.07
MSC 33.0 2.9 36.4 4.1 0.15
SC (n  11) versus placebo (n  8). *p  0.003. †p  0.01. ‡p  nonsigniﬁcant.
 left ventricular end-diastolic; LVEDV left ventricular end-diastolic volume;
end-systolic volume; MDCT  multidetector computed tomography; MSC was able to assess the effect of intramyocardial-
delivered cell therapy compared with placebo.
These findings confirmed previous studies that used
CMR to evaluate the therapeutic potential of
intramyocardial-delivered MSC in animals with
HF with chronic infarct scars (6,18). This study
introduces MDCT imaging as an alternative car-
diac imaging technique to determine efficacy of
novel myocardial therapeutics.
Myocardial infarct scar assessment by MDCT. MDCT
has the capability to distinguish between viable and
nonviable myocardium with DCE for the detection
of acute and chronic infarct scars, and its use has
recently been reported in animal experiments and
human studies; however, it is still considered an
investigative technique (9–11,16,19). After intrave-
nous delivery, iodine-based contrast agents accu-
mulate in myocardial tissue damaged by MI. The
discrimination between viable and nonviable myo-
cardium results from increased attenuation values
caused by the accumulation of iodine molecules in
the infarct area detected by MDCT. This is in
contrast to enhancement mechanisms by CMR that
rely on alteration of the contrast media via interac-
tions with water molecules (9). The infarct sizes
detected by DCE-MDCT in this study were sig-
nificantly smaller than matching CMR values; these
results are in accordance with previously published
data for acute and chronic MI (16,20). Thus,
DCE-MDCT– and DCE-CMR–derived values
for infarct size and infarct volume should not be
used interchangeably at the current status of
MDCT technology.
The extent of contrast enhancement detected by
CMR has been shown to predict the response to
medical treatment in patients with HF (21). Re-
duction of infarct size has been noted with DCE-
CMR following myocardial cell therapy in animal
studies and patients (4–6,22,23). Thus, quantifica-
tion of infarct size and infarct volume by DCE-
MDCT could be a valuable surrogate endpoint,
allowing the prediction of response to therapy.
DCE-MDCT currently offers the highest spatial
resolution for transmural characterization of infarct
scars, and this can be particularly helpful in guiding
intramyocardial delivery of cell-based therapies.
An akinetic segment might be deemed nonviable
by nuclear techniques using limited spatial reso-
lution but shows some viability in DCE-MDCT,
which increases the likelihood that this segment
will eventually recover with therapeutic interven-Figure 2.
All placebo
infarct volu
reduced in
mals (n 
decreased
MSC-treateTable 1. Infarct Value
Parameter
Infarct size, % of LV m
Total infarct volume, m
LVED mass, g
LV ejection fraction, %
Stroke volume, ml
LVEDV, ml
LVESV, ml
Values are mean  SEM. M
§p  0.02. p  0.047.
LV left ventricular; LVED
LVESV  left ventriculartion (24).
tion
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1289Evaluation of cardiac function and volumes by MDCT.
Evaluation of cardiac function with MDCT is
accomplished with intravenous injection of iodine-
based contrast agents for opacification of the blood
pool to delineate the borders of the ventricle and
application of retrospective ECG-gated protocols
to record the complete cardiac cycle during the R-R
interval. Various investigators have reported a con-
sistent overestimation of LVESV and an underes-
timation of LVEF by MDCT with 4-slice and early
16-slice technology compared with CMR; however,
with the introduction of 64-slice MDCT technol-
ogy and improvement in temporal resolution, these
intermethod differences in global LV function vari-
ables are no longer reproduced. Temporal resolu-
tion, based on gantry rotation, has been reported to
be less than 165 ms with single-source systems and
Figure 3. Quantitative Assessment of MDCT and CMR Values
The relation between MDCT and cardiac magnetic resonance (CMR
ume was evaluated for 16 animals at both time points. (A and B) M
8-mm slice thickness, respectively, with an underestimation of infar
sis. (C and D) Good correlation of infarct volume with less underes
relation of both modalities with minimal underestimation of LVEF b
Table 2. Interobserver Variability for MDCT
Parameters
Correlation
Coefﬁcient (r)
95% CI
for r
Infarct size, % of LV mass 0.96 0.93–0.98
Infarct volume, ml 0.98 0.95–0.99
LVED mass, g 0.84 0.71–0.92
LV ejection fraction, % 0.93 0.87–0.96
Stroke volume, ml 0.84 0.70–0.91
ED volume, ml 0.92 0.84–0.96
ES volume, ml 0.93 0.86–0.96
CI  conﬁdence interval; ED  end-diastolic; ES  end-systolic; other abbreviavolume. Abbreviations as in Figures 1 and 2.83 ms with dual-source MDCT technology (7).
Our results are in accordance with studies compar-
ing single-source and dual-source 64-slice
MDCT—with CMR showing small differences
between both modalities and narrow Bland-Altman
windows (25–29). In our study, we observed good
correlation coefficients for LVEDV and LVEF, and
we were able to confirm the linear relationship
between both volumetric imaging techniques for LV
function and LV remodeling parameters, making both
tomographic imaging methods interchangeable for
LV function and LV volume assessment.
Evaluation of the cardiac structure, LV volumes,
and LV function—specifically LVEF—is an inte-
gral step in determining prognosis and therapy for
patients with HF (30). Human trials, using a variety
of cell-therapy approaches, have used improve-
infarct size, infarct volume, LVEF, and LV end-diastolic (ED) vol-
T and CMR showed a fair correlation for infarct size at 4-mm and
ze by DCE-MDCT compared with DCE-CMR in Bland-Altman analy-
tion by DCE-MDCT than that for infarct size. (E and F) Good cor-
DCT. (G and H) MDCT and CMR show excellent correlation of ED
Signiﬁcance Level
(p Value)
Difference
(Mean)
95% CI for
Mean
0.0001 0.6 3.0 to1.8
0.0001 0.05 0.8 to0.7
0.0001 0.9 3.9 to5.7
0.0001 1.1 4.8 to7.0
0.0001 0.1 5.2 to5.3
0.0001 3.1 14.9 to8.7
0.0001 3.2 12.7 to6.2
s as in Table 1.) for
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1290ments in LVEF as an endpoint (3). Compared with
volumetric changes, using LVEF as an endpoint has
the advantage of denoting a survival difference and
is an accepted surrogate measure for mortality (31).
The magnitude of treatment effect on LVEF seen
in these trials has ranged from 5% to 9%, whereas
the change in the control groups has ranged from
2% to 4% (32).
Advantages and limitations of MDCT imaging. As a
novel cardiac imaging option for LV function and
viability, MDCT offers some solutions for the
difficulties faced in CMR. MDCT can be safely
performed in patients with metallic implants,
such as pacemakers, defibrillators, and prostheses,
who are inappropriate candidates for CMR. Al-
though CMR is considered the reference stan-
dard for cardiac function and myocardial viabil-
ity— based on the accuracy and reproducibility of
measurements—the duration of CMR acquisi-
tions with multiple prolonged breath-holds are
required to obtain adequate datasets, are time
consuming, and are impossible in patients with claus-
Table 3. Correlation and Bland-Altman Analysis of MDCT and C
Parameters
Correlation
Coefﬁcient (r)
Linear Regression
Equation
Infarct size, % LV mass
Total 0.70 y 0.9x 9.4
Week 12 0.37 y 0.5x 14.1
Week 24 0.89 y 1.0x 7.5
Placebo 0.44 y 0.5x 15.4
MSC 0.82 y 1.1x 6.1
Total infarct volume, ml
Total 0.81 y 1.3x 1.9
Week 12 0.68 y 1.2x 2.3
Week 24 0.87 y 1.3x 1.9
Placebo 0.73 y 1.1x 2.7
MSC 0.86 y 1.5x 1.2
LV ejection fraction, %
Total 0.90 y 1.1x 3.2
Week 12 0.87 y 1.1x 2.4
Week 24 0.92 y 1.1x 3.5
Placebo 0.88 y 1.4x 12.1
MSC 0.91 y 1.0x 3.6
ED volume, ml
Total 0.82 y 0.7x 19.3
Week 2 0.84 y 0.6x 23.6
Week 24 0.81 y 0.8x 12.2
Placebo 0.81 y 0.7x 18.5
MSC 0.81 y 0.7x 15.9
Total: n  32; week 12, week 24, placebo, MSC: n  16.
CMR  cardiac magnetic resonance; other abbreviations as in Tables 1 and 2trophobia. Thus, CMR is limited to specialized centers, twhich is in contrast to the widely accessible cardiac
MDCT. MDCT imaging is fast and offers good tem-
poral and excellent spatial resolution; however, MDCT
acquisitions require iodinated contrast agents and involve
radiation exposure.
Future perspective. To translate cardiac function
nd viability assessment with MDCT into clini-
al trials, standardized low-dose protocols are
eeded, especially to minimize overall radiation
xposure because follow-up studies are required
or outcome assessment. In the latest generation
f MDCT scanners, ECG-gated tube current
odulations are commonly applied in retrospec-
ive acquisitions for evaluation of cardiac function
7). Low-dose DCE protocols have been reported (9).
e recently described a prospectively gated protocol for
igh-resolution DCE-MDCT imaging that lowered the
adiation dose by an order of magnitude (33).
In addition to cardiac function and viability,
DCT is able to assess MBF. Cardiac CT perfu-
ion is based on the same first-pass principle as
MR (14), which has been used to evaluate cell
Signiﬁcance
Level
(p Value)
Mean Difference
(Bias) SD
95% CI for
Mean
0.0001 7.5 4.27 0.8 to15.9
0.16 7.5 5.23 3.0 to18.0
0.0001 7.5 3.06 1.7 to13.3
0.09 7.4 4.22 1.7 to16.5
0.001 7.6 4.07 0.2 to15.4
0.0001 3.2 1.71 0.3 to6.6
0.004 3.0 1.77 0.3 to6.4
0.0001 3.3 1.76 0.3 to6.9
0.001 3.3 1.94 0.4 to7.0
0.0001 3.0 1.53 0.3 to6.2
0.0001 0.9 3.81 6.6 to8.5
0.0001 0.9 3.69 6.1 to8.0
0.0001 0.9 4.19 7.3 to9.1
0.0001 0.3 3.43 7.6 to7.0
0.0001 2.2 3.78 5.0 to9.6
0.0001 0.02 6.63 15.9 to16.0
0.001 1.2 5.90 15.7 to18.0
0.001 1.1 7.44 16.3 to14.1
0.001 3.1 6.38 11.1 to17.3
0.001 3.0 7.10 18.8 to12.7MRherapy (5). Semiquantitative and quantitative as-
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1291sessments of MBF with MDCT have been reported
in experimental animals (9,13). Cardiac MDCT is
poised to offer a comprehensive evaluation of novel
myocardial therapeutics.
Figure 4. Comparison of MDCT and CMR Values for MI and LVE
Data of placebo- (n  8) and MSC-treated (n  8) animals imaged
the absolute difference of MDCT and MRI values, effectiveness of M
(∆change). (A and B) Both DCE-MDCT and DCE-CMR detected signi
(C) The changes over time showed a fair correlation between MDC
as infarct volume was compared (p  0.0001), showing a modest c
with MDCT and CMR. Importantly, the effectiveness of MSC therapy
were not signiﬁcantly different between MDCT and CMR evaluation
Table 4. Comparison of MDCT and CMR Studies (N  32)
Parameter Groups
Pla
Week 12
Infarct size, % of LV mass MDCT 13.8 1.3
CMR 20.1 1.6
Total infarct volume, ml MDCT 4.5 0.5
CMR 7.1 0.8
LVED mass, g MDCT 35.0 1.4
CMR 37.3 2.5
LV ejection fraction, % MDCT 33.3 1.4
CMR 34.0 2.6
ED volume, ml MDCT 60.1 5.7
CMR 56.6 4.7
Week 24: MSC (n  8) versus placebo (n  8). *p  0.01. †p  0.001. ‡p  0.
Abbreviations as in Tables 1, 2, and 3.a good correlation for LVEF evaluation with MDCT and CMR. AbbreviatiStudy limitations. This animal study was conducted
without any medical therapy given to patients after
MI. Therefore, the chronic MIs expanded and the
infarct size increased in the placebo group, consis-
ssessment
he same day with both modalities were compared to evaluate
therapy, and correlation of the evaluated changes over time
t differences of infarct size with MSC therapy (p  0.0001).
d CMR assessment. (D to F) These differences were also apparent
lation of both modalities. (G and H) Values for LVEF were similar
s apparent with both imaging modalities, and detected changes
the studied animals (p  0.06). (I) The ∆change analysis showed
o
p Value
MSC
Week 24 Week 12 Week
16.3 1.6 0.02 14.5 1.4 9.4 1
24.9 1.1 0.03 23.3 2.1 15.8 2
5.9 0.7 0.002 4.4 0.5 3.5 0
9.9 0.9 0.03 7.8 0.9 6.0 1
37.8 1.4 0.08 33.5 1.6 39.4 2
41.3 2.4 0.16 32.2 1.9 37.8 1
29.1 1.5 0.03 34.7 2.5 38.5 3
27.8 1.9 0.01 35.9 2.6 41.7 3
67.6 4.1 0.16 48.7 4.0 54.7 3
65.1 2.5 0.08 50.2 3.5 53.5 4
p  0.02. p  0.003. ¶p  0.04.F A
on t
SC
ﬁcan
T an
orre
wa
s inceb
p Value24
.7* 0.005
.0† 0.01
.7‡ 0.04
.1‡ 0.04
.8 0.10
.4 0.05
.2§ 0.02
.3 0.02
.8¶ 0.44
.69¶ 0.67
03. §ons as in Figures 1, 2, and 3.
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1292tent with results from a clinical study using nonin-
vasive imaging techniques conducted in the early
1980s (34). With modern medical therapy, de-
creases in infarct size are anticipated in chronic MI,
as shown in a recent CMR study (35). To compli-
cate matters, additive effects of angiotensin-
converting enzyme inhibition with beta-blockade in
combination with cell therapy have been described
(36). Although these limitations are evident in the
current study, the goal of this study was to demon-
strate the usefulness of MDCT to evaluate the
effect of myocardial therapies.
However, there are some limitations that may
affect the transfer of the reported MDCT protocols
and results to human trials. First, the animals
presented had elevated heart rates, which are usually
considered a relative contraindication for MDCT.
Although the reported MDCT protocols proved
reliable even under these unfavorable conditions,
patients with elevated heart rates above 60 to 70
beats/min may receive negative chronotropic med-
ication to reduce the heart rate for coronary CT
angiography. This will affect the value of functional
analysis because ventricular volumes change if beta-
blockers are applied; however, beta-blockers only
have to be given if coronary CT angiography is
mandated. Second, no tube current modulation was
applied, as is routinely done now in patient studies
to reduce radiation exposure. Increased image noise
on systolic images of ECG-gated tube currentPhysiol 2008;294:H2002–11.
1
comparison with cregional LV function assessment. Third, because of
the passive contrast kinetics of iodine-based con-
trast agents and the limited collateral circulation in
pigs, DCE-MDCT imaging of chronic infarct scars
in this animal model required a relatively large dose
of iodine to cause a sufficient change in the volume
distribution in the myocardial bed. In this study,
we used 1.5 times a human equivalent dose,
although successful viability imaging in humans
has been reported in several studies with standard
contrast volumes used for coronary CT angiog-
raphy (37).
C O N C L U S I O N S
This animal study suggests that cardiac MDCT can
be reliably used to evaluate infarct size, infarct
volumes, LV volumes, and LV function after
intramyocardial-delivered MSC therapy with sen-
sitivity similar to CMR and showing similar
changes at follow-up. These findings support the
use of cardiac MDCT in preclinical and clinical
studies as a noninvasive imaging technique for
detecting therapeutic effects of novel myocardial
therapies.
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